You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

EMERGING THERAPIES

Demchuk, Andrew M.; Gupta, Rishi; Khatri, Pooja

CONTINUUM: Lifelong Learning in Neurology:
doi: 10.1212/01.CON.0000275642.92203.b0
Article
Abstract

Acute stroke therapies are evolving gradually. The heterogeneity of stroke has made it difficult to achieve success in large randomized trials. There appears to be "no shoe that fits all" in stroke treatment other than early systemic thrombolysis using recombinant tissue-type plasminogen activator (rt-PA), which succeeds by achieving early recanalization, thereby limiting infarct extent. Many lessons have been learned that have refined our approach to developing new treatments. Emerging therapies for stroke can be classified into a few basic themes. In ischemic stroke, promising therapies are aimed at optimizing arterial recanalization through combined systemic drugs, ultrasound-enhanced treatment, or the use of interventional techniques, such as intraarterial tissue plasminogen activator, Merci® catheter, or a combined systemic/interventional approach. Neuroprotection treatment remains elusive, although strategies to initiate ultra-early (ambulance-based) neuroprotection appear justified. Collateral flow augmentation techniques appear promising in improvement of cerebral blood flow via this backdoor approach. The extension of treatment windows beyond the first 3 hours is reliant on neurovascular imaging techniques such as CT perfusion and multimodal MRI to detect significant penumbra.

Author Information

Relationship Disclosure: Dr Demchuk has received personal compensation for activities with AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., and sanofi-aventis. Dr Demchuk has received grant support from Novo Nordisk, Inc. Dr Gupta has received personal compensation for activities with Concentric Medical, Inc. Dr Khatri has nothing to disclose.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Demchuk discusses the unlabeled use of emerging therapies with numerous references to potential therapies. Dr Gupta has nothing to disclose. Dr Khatri discusses the unlabeled use of the Merci Retriever® device and intraarterial rt-PA.

© 2008 American Academy of Neurology